MINERVAX
Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.
MINERVAX
Industry:
Biotechnology Health Care Life Science Medical Wellness
Founded:
2010-01-01
Address:
Hellerup, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.minervax.com
Total Employee:
1+
Status:
Closed
Email Addresses:
[email protected]
Total Funding:
81.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Apple Mobile Web Clips Icon WordPress Font Awesome Mobile Non Scaleable Content Euro Organization Schema Google Maps
Similar Organizations
Editas Medicine
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company that develops new medicines to treat patients with rare genetic diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
VectivBio
VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
Sanofi Ventures
Sanofi Ventures investment in Series B - Minervax
Wellington Partners
Wellington Partners investment in Series B - Minervax
LF Investment
LF Investment investment in Series B - Minervax
Repair Impact Fund
Repair Impact Fund investment in Series B - Minervax
Industrifonden
Industrifonden investment in Series B - Minervax
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Series B - Minervax
Adjuvant Capital
Adjuvant Capital investment in Series B - Minervax
Novo Holdings
Novo Holdings investment in Grant - Minervax
Repair Impact Fund
Repair Impact Fund investment in Grant - Minervax
Sunstone Life Science Ventures
Sunstone Life Science Ventures investment in Grant - Minervax
Official Site Inspections
http://www.minervax.com Semrush global rank: 6.13 M Semrush visits lastest month: 1.32 K
- Host name: linux213.curanet.dk
- IP address: 94.231.106.153
- Location: Denmark
- Latitude: 55.7123
- Longitude: 12.0564
- Timezone: Europe/Copenhagen
More informations about "Minervax"
Welcome To MinervaX | Developing life-saving vaccines
We are supported by leading blue-chip healthcare funds. Our state-of-the-art vaccine targets important unmet medical needs. We aim to prevent adverse pregnancy outcomes and life …See details»
MinervaX - EQT Group
6 days ago · MinervaX is a biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus. Subscribe to EQT's press releases, regulatory press releases …See details»
Minervax ApS - LinkedIn
MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is...See details»
MinervaX Announces Completion of Enrolment in Phase I Clinical …
MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. …See details»
MinervaX provides clinical and leadership update - PR Newswire
COPENHAGEN, Denmark, Oct. 7, 2021 /PRNewswire/ -- MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), …See details»
Denmark: EIB supports development of novel maternal …
Dec 15, 2022 · The European Investment Bank (EIB) has announced today that it has provided a €50 million loan facility to MinervaX ApS, a privately held Danish biotechnology company developing a novel, protein-based vaccine against …See details»
MinervaX appoints Lidia Oostvogels as Chief Medical Officer and ...
COPENHAGEN, Denmark, Jan. 5, 2023 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), …See details»
MinervaX Commences First Phase 1 Clinical Study of Novel GBS …
MinervaX has completed enrolment and dosing of its 2nd phase II clinical trial of its novel GBS vaccine in pregnant women across Denmark, the UK and South Africa. Details of MinervaX’s …See details»
Minervax | LU Innovation
These bacteria are carried by around one in four women. Professor Gunnar Lindahl and Dr Thomas Areschoug have now developed a possible vaccine against the infection. The vaccine …See details»
Biotech Entrepreneur Veronica Gambillara Fonck Appointed Chair …
COPENHAGEN, Denmark, Nov. 14, 2024 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B …See details»
Minervax raises €47.4m in Series B funding round for GBS shot
6 days ago · Denmark’s MinervaX has raised €47.4 million (around $56 million) in a Series B funding round to take its novel group B streptococcus (GBS) vaccine into mid-stage clinical trials.See details»
MinervaX initiates Phase I GBS vaccine trial in older people
Apr 18, 2023 · MinervaX has initiated a Phase I clinical trial of its new GBS vaccine to assess the safety and immunogenicity in the older adult population with Group B Streptococcus (GBS). …See details»
MinervaX raises upsized EUR 47.4M (USD 57M) Series B to …
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ -- MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), …See details»
Danish biotech startup names Veronica Gambillara Fonck as Chair …
Nov 18, 2024 · MinervaX, a Copenhagen-based biotech company focused on developing a vaccine for Group B Streptococcus (GBS), has appointed Veronica Gambillara Fonck as Chair …See details»
MinervaX and Wacker Biotech Announce Manufacturing …
Sep 17, 2024 · MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund …See details»
MinervaX provides clinical and leadership update - Nasdaq
COPENHAGEN, Denmark, Oct. 7, 2021 /PRNewswire/ -- MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), …See details»
MinervaX and Wacker Biotech Announce Manufacturing …
MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. …See details»
MinervaX and Wacker Biotech Announce Manufacturing …
Sep 17, 2024 · MinervaX is a Danish biotechnology company, established in 2010 to develop a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund …See details»
Danish biotech startup MinervaX collects €72M to advance …
Dec 20, 2022 · Copenhagen-born biotechnology startup MinervaX has secured €22 million in an equity funding round co-led by new investors Trill Impact Ventures and Pureos Bioventures …See details»
MinervaX announces 72M EUR financing to advance development …
COPENHAGEN, Denmark, Dec. 15, 2022 /PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), …See details»